B+
Bull case
25%
Probability
Target price
$55.00
Analysis reference price unavailable
Analysis 2026-10-01 · RankAlpha Sentiment Codex
LQDA
LiquidiaFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
A remedy limited to PH-ILD labeling, continued PAH availability, and a successful appeal could preserve substantial value in the franchise. The pre-ruling Q2 sales and profitability demonstrate commercial traction, but cannot establish post-ruling earnings power.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -1.4.
What can break
A remedy could extend beyond removing PH-ILD from the label and restrict YUTREPIA availability more broadly. [#PR-2026-09-30]
Momentum
2
Value
59
Sentiment
20
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $28.00 · Bull $55.00 · Bear $10.00Analysis 2026-10-01; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-01 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $54.38
Why
Momentum2 · Δ7d +0.4
Value59 · Δ7d -1.4
Sentiment20 · Δ7d -16.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -1.4.
Contradictions & invalidation
- • A remedy could extend beyond removing PH-ILD from the label and restrict YUTREPIA availability more broadly. [#PR-2026-09-30]
- • Pre-ruling sales, profitability, and analyst forecasts may overstate earnings under a restricted label. [#SEC-8K-2026-08-12]
- • A broader product interruption, delayed relabeling, or damages could impair the dominant commercial asset.
Catalyst clock
2026-10-07
Court remedy for YUTREPIA patent infringement
Lead driver: Value · See fundamentals
Momentum
2
8% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
-3.1
Value
59
47% active weight
Current posture
7d trendSoftening
Δ7d
-1.4
Δ21d
-3.1
Sentiment
20
45% active weight
Current posture
7d trendSoftening
Δ7d
-16.1
Δ21d
-43.8
Why this grade
Composite grade F. Momentum 1.8 / Value 59.0 / Sentiment 19.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-01. Scenario method
Most likely
B
Base case
40%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-10-01 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-10-01 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$3.82B
Beta
0.47
Shares Out
89.51M
P/E (TTM) · Derived
-53.3
P/S (TTM)
40.41
P/FCF (TTM) · Derived
28.92
Rev YoY
+1842.7%
EPS YoY
-251.7%
Gross Margin
+92.3%
Op Margin
+37.4%
Net Debt
$7.25M
Current Ratio
2.31
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data